Cargando…
Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactiviti...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033468/ https://www.ncbi.nlm.nih.gov/pubmed/35480952 http://dx.doi.org/10.1039/d1ra01361k |
_version_ | 1784692895975997440 |
---|---|
author | Wiriyachaiporn, Natpapas Sirikaew, Siriwan Chitchai, Nawakarn Janchompoo, Pareena Maneeprakorn, Weerakanya Bamrungsap, Suwussa Pasomsub, Ekawat Japrung, Deanpen |
author_facet | Wiriyachaiporn, Natpapas Sirikaew, Siriwan Chitchai, Nawakarn Janchompoo, Pareena Maneeprakorn, Weerakanya Bamrungsap, Suwussa Pasomsub, Ekawat Japrung, Deanpen |
author_sort | Wiriyachaiporn, Natpapas |
collection | PubMed |
description | A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactivities and were used as targeting ligands. With the best antibody pairs selected, the system exhibited good specificity to both viruses without cross reactivity to other closely related respiratory viruses. Further semi-quantitative analysis using a strip reader revealed that the system is capable of detecting influenza A and B protein content as low as 0.04 and 1 ng per test, respectively, using a sample volume as low as 100 μL, within 10 minutes (R(2) = 0.9652 and 0.9718). With a performance comparison to the commercial tests, the system demonstrated a four-to-eight-fold higher sensitivity. Pre-clinical evaluation with 101 nasopharyngeal swabs reveals correlated results with a standard molecular approach, with 89% and 83% sensitivity towards influenza A and B viruses, and 100% specificity for both viruses. |
format | Online Article Text |
id | pubmed-9033468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-90334682022-04-26 Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications Wiriyachaiporn, Natpapas Sirikaew, Siriwan Chitchai, Nawakarn Janchompoo, Pareena Maneeprakorn, Weerakanya Bamrungsap, Suwussa Pasomsub, Ekawat Japrung, Deanpen RSC Adv Chemistry A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactivities and were used as targeting ligands. With the best antibody pairs selected, the system exhibited good specificity to both viruses without cross reactivity to other closely related respiratory viruses. Further semi-quantitative analysis using a strip reader revealed that the system is capable of detecting influenza A and B protein content as low as 0.04 and 1 ng per test, respectively, using a sample volume as low as 100 μL, within 10 minutes (R(2) = 0.9652 and 0.9718). With a performance comparison to the commercial tests, the system demonstrated a four-to-eight-fold higher sensitivity. Pre-clinical evaluation with 101 nasopharyngeal swabs reveals correlated results with a standard molecular approach, with 89% and 83% sensitivity towards influenza A and B viruses, and 100% specificity for both viruses. The Royal Society of Chemistry 2021-05-24 /pmc/articles/PMC9033468/ /pubmed/35480952 http://dx.doi.org/10.1039/d1ra01361k Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Wiriyachaiporn, Natpapas Sirikaew, Siriwan Chitchai, Nawakarn Janchompoo, Pareena Maneeprakorn, Weerakanya Bamrungsap, Suwussa Pasomsub, Ekawat Japrung, Deanpen Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications |
title | Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications |
title_full | Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications |
title_fullStr | Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications |
title_full_unstemmed | Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications |
title_short | Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications |
title_sort | pre-clinically evaluated visual lateral flow platform using influenza a and b nucleoprotein as a model and its potential applications |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033468/ https://www.ncbi.nlm.nih.gov/pubmed/35480952 http://dx.doi.org/10.1039/d1ra01361k |
work_keys_str_mv | AT wiriyachaipornnatpapas preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT sirikaewsiriwan preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT chitchainawakarn preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT janchompoopareena preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT maneeprakornweerakanya preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT bamrungsapsuwussa preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT pasomsubekawat preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications AT japrungdeanpen preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications |